← Eichor
Study identifier: NCT06762678 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Transcriptomic Approach for the Identification and Prioritization of Genome Variants in Neurodevelopmental Disorders With Malformation

Condition: Neurodevelopmental Disorders and Developmental Abnormalities  ·  Sponsor: University Hospital, Angers

PhaseNA
Planned participants58
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

Three million persons in France are impacted by rare diseases. Amid the 7000 different diseases which are identified today, neurodevelopmental disorders are the main symptoms found interesting 35 000 birth every years, according to the French Health Authority. In half of these cases, patients are under 5 years old and a molecular diagnosis is only available in 50% of them, associated with a diagnostic wandering exceeding 5 years for 25% of every patients. High throughput DNA sequencing technologies are powerful tools to elucidate new causative variants. Although the diagnostic yield was refined by DNA-seq, data interpretation and technology limits remain the two major obstacles which still need be overcame. Missing a molecular diagnosis through a genomic approach alone highlight the need to integrate multi-omic approaches such as Ribonucleic Acid sequencing. This sequencing level allows new insight such like the evidence of aberrant gene expression, mono allelic allele expression, or abnormal alternative splicing. It makes possible too, to detect variants which are unable to be found via genome sequencing only. Recently, a diagnostic performance improvement has been described trough the association of the two technics, i.e. Ribonucleic Acid-seq and genome sequencing, in a context of neuromuscular diseases. However, only few studies were carry out on neurodevelopmental disorders in addition with malformative features. Angers's team demonstrated by the end of 2022, a diagnost…

This description comes directly from the study's public registry record.

Talk to the study team

Estelle COLIN, MD, PhD  ·  02 41 35 36 37  ·  estelle.colin@chu-angers.fr

Always discuss trial participation with your own doctor first.

Locations (7)

University Hospital of AngersAngers, FranceRecruiting
University Hospital of BrestBrest, FranceRecruiting
Le Mans Hospital CenterLe Mans, FranceRecruiting
University Hospital of NantesNantes, FranceNot Yet Recruiting
University Hospital of RennesRennes, FranceRecruiting
University Hospital of ToursTours, FranceNot Yet Recruiting
Vannes Hospital CenterVannes, FranceNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06762678